Fulvestrant, a selective estrogen receptor down-regulator (SERD), which blocks the proliferation of breast carcinoma cells (Wakeling et al., 1991), is an effective endocrine treating process for women with hormone-sensitive advanced breast carcinoma. Here, ESR1 is linked to breast carcinoma.